Content
Angitia Biopharmaceuticals
completed $120 million Series C Round funding. Investors include
Bain Capital Ventures (lead), Janus Henderson Investors, OrbiMed Advisors, Legend Capital, 3H Health Investment.
About
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.
Startup
Angitia Biopharmaceuticals
https://www.angitiabio.com
Claim Profile
Location:
Woodland Hills, CA USA
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.


Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
